TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC
NCT05332821
·
clinicaltrials.gov ↗
COMPLETED
Status
1244
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
PROCEDURE:
TACE
Sponsor
Zhongda Hospital